NeoGenomics is an oncology diagnostics company trading at a compelling 18% potential upside relative to analyst price targets, but weak quality metrics and an unfavorable risk/reward profile at current levels make the investment speculative until margin improvement materializes.
Thesis pillars
- Oncology Diagnostics Revenue Growth→Stable
- Earnings Beat Momentum↑Improving
- Valuation Growth Combination→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 17, 2026
NeoGenomics, Inc. (NEO) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $17.27: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10. Specifically: High short interest: 13%; Below-average business quality.
NeoGenomics provides oncology diagnostic testing and consultative services through a network of CAP-accredited, CLIA-certified laboratories in Florida, California, North Carolina, New Jersey, Texas and the United Kingdom, offering cytogenetics, FISH, flow cytometry,... Read more
Sell if holding. Engine safety override at $17.27: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10. Specifically: High short interest: 13%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.2/10, moderate confidence.
Passes 4/7 gates (positive momentum, clean insider activity, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 0d<=7d. Suitability: aggressive.
Recent developments
updated 2026-10-28Recent Developments — NeoGenomics, Inc.
Latest news
- NEWS NeoGenomics Receives 2026 Asset Excellence Recognition — fiscal.ai Oct 27, 2026 positive
- NEWS Neo Performance Materials Appoints Scott Stout as Chief Revenue Officer — fiscal.ai Oct 26, 2026 positive
- NEWS Neo Performance Materials Inc. Third Quarter 2026 Earnings Release & Conference Call — fiscal.ai Oct 21, 2026 neutral
- NEWS Neo Performance Materials Invited to Prepare €126M EU Innovation Fund Grant Agreement — fiscal.ai Oct 20, 2026 positive
- NEWS NeoGenomics Announces Expanded Partnership With Indica Labs To Scale Digital Pathology Using HALO AP Platform; Terms Not — benzinga Oct 15, 2026 positive
Generated 2026-10-28T11:33:56Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-06-25Item 5.02LOWOn June 23, 2026 NeoGenomics' Board expanded to ten directors and appointed Carolyn S. Starrett to fill the new seat, effective immediately. Routine board appointment; she will serve until the 2027 annual meeting.SEC filing →
- 2026-05-22Item 5.02LOWAt NeoGenomics' May 21, 2026 annual meeting, stockholders approved a second amendment to the 2023 Equity Incentive Plan, adding 5,000,000 shares available for issuance. Routine equity-plan increase.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Unprofitable operations — net margin -6.8%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $17.27: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10. Specifically: High short interest: 13%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $16.06. Score 6.2/10, moderate confidence.
Analyst target: $19.01 (+10.1% upside). Prior stop was $16.06. Stop-loss: $16.06.
Quality below floor (3.7 < 4.0).
NeoGenomics, Inc. trades at a P/E of N/A (forward 50.4). TrendMatrix value score: 7.0/10. Verdict: Sell.
16 analysts cover NEO with a consensus score of 3.9/5. Average price target: $22.
What does NeoGenomics, Inc. do?NeoGenomics provides oncology diagnostic testing and consultative services through a network of CAP-accredited,...
NeoGenomics provides oncology diagnostic testing and consultative services through a network of CAP-accredited, CLIA-certified laboratories in Florida, California, North Carolina, New Jersey, Texas and the United Kingdom, offering cytogenetics, FISH, flow cytometry, molecular/NGS testing and molecular residual disease (MRD) monitoring. The company serves community pathology practices, hospital labs, academic centers and pharmaceutical companies, competing against Quest Diagnostics, LabCorp, Guardant Health, Natera and Myriad Genetics. No single client accounted for more than 10% of NeoGenomics